New drug combo tested to shrink rare, aggressive bladder cancer before surgery
NCT ID NCT06091124
Summary
This study is testing whether a combination of three drugs (adebrelimab, etoposide, and cisplatin) given before bladder removal surgery can help shrink or eliminate a rare and aggressive form of bladder cancer called neuroendocrine carcinoma. About 22 patients with this specific cancer type will receive up to four cycles of the drug combination, followed by surgery. The main goals are to see if the treatment completely eradicates the cancer in the removed bladder and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
RenJi Hospital
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xi'an Jiao Tong University
RECRUITINGXi'an, Shaanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Hospital of Tianjin Medical University
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
West China Hospital
RECRUITINGChengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.